SIGASIGA TECHNOLOGIES INC
Pharmaceutical Preparations
- Revenue
- $95M
- 32% YoY
- Operating margin
- 25.1%
- 50% YoY
- EBITDA
- $24M
- 66% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- -4.8×
- −$116M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear187% of net incomeCash flow under 80% of net income
- Dilutive SBCClear4% of revenueOver 10% of revenue
- Payouts exceed cash flowClear99% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear1% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $134M | $111M | $140M | $139M | $95M | 32% |
| Operating income | $89M | $43M | $84M | $70M | $24M | 66% |
| Net income | $69M | $34M | $68M | $59M | $23M | 61% |
| Operating cash flow | $11M | $42M | $95M | $49M | $43M | 11% |
| Stock-based comp | $1M | $2M | $2M | $4M | $4M | 1.2% |
| Buybacks | $26M | $13M | $11M | $0 | $0 | |
| Dividends | $0 | $33M | $32M | $43M | $43M | 1.1% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $3M | $4M | 116 | 120 |
| FY2024 | $5M | $6M | 104 | 91 |
| FY2023 | $2M | $2M | 88 | 92 |
| FY2022 | $2M | $2M | 107 | 89 |
| FY2021 | $2M | $2M | 103 | 99 |